Form 4: Revolution Medicines CEO Mark Goldsmith Exercises Significant Stock Options
Insider Transaction Report
Revolution Medicines, Inc. CEO Mark A. Goldsmith reported the exercise of 37,000 stock options, increasing his direct beneficial ownership in the company.
Summary
- Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, Inc. (RVMD), reported changes in his beneficial ownership of company securities.
- On June 30, 2025, Goldsmith exercised 37,000 stock options at an exercise price of $0.54 per share, acquiring common stock.
- Following this transaction, Goldsmith directly holds 465,720 shares of common stock, which includes 218,188 restricted stock units.
- Goldsmith also indirectly holds 20,424 shares through the Jonathan Goldsmith Revocable Trust, 20,424 shares through the Rebecca Eve Goldsmith Trust, and 465,604 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
- After the exercise, Goldsmith retains 168,503 unexercised stock options directly.
Sentiment
Score: 7
Explanation: The exercise of stock options by the President and CEO suggests confidence in the company's future prospects and potential for share price appreciation.
Positives
- The exercise of stock options by President and CEO Mark A. Goldsmith indicates a direct investment and confidence in Revolution Medicines, Inc.'s future performance.
- The exercise price of $0.54 suggests the options were significantly in-the-money, implying potential value creation for the company.
Future Outlook
This Form 4 filing does not provide forward-looking statements or guidance.
Industry Context
This filing reports an individual insider transaction and does not provide broader industry context.
Stakeholder Impact
- Shareholders may view the CEO's exercise of stock options as a positive signal, indicating management's confidence in the company's value and future performance.
Key Dates
| Date | Description |
|---|---|
| 03/01/2022 | Date when the exercised stock options became exercisable. |
| 06/30/2025 | Date of the reported transaction (exercise of stock options). |
| 07/02/2025 | Date the Form 4 filing was signed. |
| 02/11/2028 | Expiration date of the exercised stock options. |
Keywords
Revolution Medicines, RVMD, Mark A. Goldsmith, Stock Options, Insider Transaction, Beneficial Ownership, SEC Form 4, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.